24.3 billion USD stock-swap merger! Two North American chemical giants merge—hidden industry pain point: Can the long-standing 'chlor-alkali co-production deadlock' truly be broken?

On June 16, Olin Corporation—the largest chlor-alkali producer in the United States—announced it would acquire Huntsman Corporation via an all-stock transaction. Under the terms, each Huntsman share will be exchanged for 0.5476 shares of Olin stock, valuing the deal at approximately USD 2.43 billion. Upon completion, Olin shareholders will hold 54.5% of the combined company, while Huntsman shareholders will hold 45.5%. The merged entity will become a North American chemical powerhouse, with projected combined 2025 revenues of roughly USD 12.5 billion. On the surface, this appears to be a typical scale-driven consolidation within the chemical industry. Yet anyone familiar with the fundamental constraints of the chlor-alkali industry will recognize an almost inevitable industrial logic behind this merger—the answer lies in a production ratio known as the ECU (Electrochemical Unit). The Chlor-Alkali Industry’s Bundling Dilemma To understand this merger, one must first grasp a core constraint of chlor-alkali manufacturing: the ECU ratio (Electrochemical Unit). In chlor-alkali electrolysis, producing 1 metric ton of chlorine gas (Cl₂) simultaneously yields approximately 1.1 tons of caustic soda (NaOH) and 0.03 tons of hydrogen gas (H₂). These three products are intrinsically co-produced—you cannot independently adjust output of any single product, nor can you halt chlorine production while continuing to produce caustic soda. This constraint creates immense commercial pressure in practice. Demand for caustic soda—used in papermaking, textiles, aluminum smelting, and other sectors—is relatively stable; by contrast, chlorine demand is highly concentrated in downstream sectors such as polyvinyl chloride (PVC) and phosgene-based chemicals (e.g., MDI, TDI), whose cyclical volatility is extreme. When chlorine markets soften, chlor-alkali producers face a dilemma: either cut overall production (reducing caustic soda output too, resulting in dual losses), or slash chlorine prices. Yet chlorine is a hazardous gas with limited transport radius and cannot be stored in large quantities over extended periods—it must be consumed locally. Olin has long struggled under precisely this constraint. A globally recognized vertically integrated chemical manufacturer and distributor—and also a leading U.S. ammunition producer—Olin’s core chemical products include chlorine, caustic soda, vinyl products, epoxy resins, chlorinated organics, bleach, hydrogen, and hydrochloric acid. Its Winchester brand manufactures and sells sporting ammunition, law enforcement ammunition, heavy-duty reloading components, small-caliber military ammunition and accessories, industrial ammunition, and clay targets. As America’s largest chlor-alkali producer, Olin sources 76% of its electricity from natural gas and hydropower—keeping power costs relatively manageable—but persistent difficulties finding outlets for its chlorine have consistently weighed on profitability. In recent years, intensifying global competition among chlorine derivatives has forced Olin to occasionally offload chlorine at steep discounts in the spot market. Screenshot from Olin’s official website Huntsman’s True Identity: The Largest Chlorine Consumer Within the chemical industry, Huntsman is commonly positioned as a polyurethane and epoxy resin company. It operates three major business units: Polyurethanes, Advanced Materials, and Functional Products. Yet viewed through the lens of chlor-alkali chemistry, Huntsman holds another, more critical identity: one of the world’s largest consumers of chlorine.

Breaking news! Olympus CEO dismissed!

On October 28, Olympus suddenly issued a notice announcing a change in its Chief Executive Officer (CEO). The notice stated that Olympus had received allegations against Stefan Kaufmann—its Director, Representative Executive Officer, President & CEO—regarding the illegal purchase of narcotics. After consulting external legal counsel, Olympus immediately launched an investigation, reported the matter to relevant authorities, and fully cooperated with the investigation. Image source: Olympus Japan official website Based on the investigation’s findings, Olympus’ Board of Directors unanimously concluded that Stefan Kaufmann’s conduct was inconsistent with Olympus’ Global Code of Conduct, core values, and corporate culture; accordingly, the Board requested his resignation. On the same day the notice was issued, Stefan Kaufmann stepped down from all related positions. A Veteran Departs After Over Two Decades Stefan Kaufmann, aged 56 and originally from Germany, was a seasoned Olympus veteran who joined the company in 2003. He assumed the roles of Director, Representative Executive Officer, President & CEO on April 1, 2023—succeeding current Director and Representative Executive Officer Yasuo Takeuchi—serving only a brief 18 months. Stefan Kaufmann took office during a period of crisis for Olympus. On March 15, 2023, the U.S. Food and Drug Administration (FDA) issued Olympus a warning letter concerning device fraud. According to the letter, FDA inspectors visited Olympus’ Tokyo factory—where endoscopes and related accessories are manufactured—between November 7 and 10, 2022. The inspection revealed that certain devices were adulterated, meaning their manufacture, packaging, storage, or installation failed to comply with current Quality System Regulation requirements. According to MedTech Insider, a former colleague of Stefan Kaufmann noted that Kaufmann’s two top priorities were resolving these regulatory issues and advancing Olympus’ core medical technology business. Since Kaufmann’s appointment, Olympus’ stock price rose 16%. However, this incident inevitably triggered significant repercussions: following the announcement on Monday, October 28, Olympus’ shares plunged 6% that same day—potentially marking the company’s largest single-day decline in nearly three months. To ensure continuity and stability in Olympus’ operations, the company swiftly implemented personnel adjustments. In its statement, Olympus confirmed that Director and Representative Executive Officer Yasuo Takeuchi would temporarily assume the CEO role, overseeing daily operations and management. From Camera Pioneer to Endoscopy Leader When people think of Olympus, many first recall its renowned camera business—but Olympus’ endoscopy division is equally iconic. Founded in 1919, Olympus successfully commercialized microscopes in Japan for the first time in 1920. It developed its first endoscope in 1950 and introduced the revolutionary half-frame camera in 1959. Olympus’ endoscope enabled humanity’s first direct visualization of the interior of the stomach—opening an entirely new door for medical advancement. Thereafter, Olympus invested heavily in R&D, continuously refining endoscope comfort and image quality.

Olin stock hits 52-week low at 17.0 USD

Sep 1, 2026

Olin Corporation's stock fell to a 52-week low of $17.02 after disappointing Q2 2026 earnings driven by volatile chemical markets and an unplanned plant outage, prompting analyst downgrades.

Investing.com India

Olin Stock Hits 52-Week Low at $17.02

Investing.com South Africa

Olin Stock Hits 52-Week Low at $17.02

Investing.com Australia

Show all reports

2026-01-09

Olin Cuts Q4 EBITDA Guidance

2026-03-31

Mizuho Issues Positive Forecast for Olin (NYSE:OLN) Stock Price

2026-04-02